Arcutis Announces Engagements at Key Upcoming Investor Events

Author: Owen Jenkins Updated: 10-27-2025 04:21 PM

Arcutis Biotherapeutics to Engage Investors

Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), a pioneering biopharmaceutical company based in California, focuses on innovations in immuno-dermatology. The company has announced its management team's participation in two forthcoming investor conferences, illustrating its commitment to fostering communication with stakeholders.

Upcoming Conference Details

Guggenheim Healthcare Innovation Conference

One of the notable events is the Guggenheim's 2nd Annual Healthcare Innovation Conference scheduled for November 10-12, 2025. Arcutis will be featured in a fireside chat on November 11, where key executives will discuss the company's strategic initiatives and product pipeline starting at 8:30 am ET.

TD Cowen Summit Participation

The TD Cowen Immunology & Inflammation Summit will follow shortly after, taking place on November 12-13, 2025. On November 12, Arcutis will again participate in a fireside chat at 9:00 am ET, further engaging with investors and industry experts on their innovative approaches in dermatology.

Accessing Conference Webcasts

For those interested in tuning in to these discussions, webcasts will be available through the 'Events' section of Arcutis’ website. A recorded version of these sessions will be accessible for 180 days after the event. The webcasts provide a great opportunity for potential investors and healthcare stakeholders to gain insights directly from the company's leadership.

About Arcutis Biotherapeutics

Arcutis is dedicated to advancing dermatological solutions to address pressing needs in the treatment of immune-mediated skin diseases. With a robust portfolio of targeted therapies that have received approval for treating major inflammatory skin conditions, they are transforming patient care in dermatology. Moreover, their innovative dermatology development platform allows them to leverage biological insights to create differentiated therapies, fostering a promising pipeline focused on inflammatory dermatological conditions.

Future of Arcutis

As the company continues to push forward in dermatological innovation, its robust pipeline reflects ongoing research and development efforts. Arcutis aims to deliver meaningful solutions that address both patient needs and market demands, showcasing its dedication to making a positive impact in the field of dermatology.

Contact Information

For media inquiries, Amanda Sheldon, Head of Corporate Communications, can be reached via email at media@arcutis.com. Investors seeking information can contact Brian Schoelkopf at ir@arcutis.com.

Frequently Asked Questions

What is the focus of Arcutis Biotherapeutics?

Arcutis Biotherapeutics specializes in developing innovative treatments for immune-mediated dermatological diseases.

Where will the upcoming investor conferences take place?

The investor conferences will be held virtually, and details will be available on the company's website.

What are the dates for Arcutis' participation?

Arcutis will participate in the Guggenheim Healthcare Innovation Conference on November 11 and the TD Cowen Immunology & Inflammation Summit on November 12.

How can investors access the conference webcasts?

Investors can access the webcasts through the 'Events' section of Arcutis' official website.

Who should media inquiries be directed to?

Media inquiries should be directed to Amanda Sheldon at media@arcutis.com.

About The Author

Hi there I'm 38-year-old author and financial consultant Owen Jenkins. Having worked in the financial sector for more than ten years, I am well-versed in the subtleties and complexity that mold our financial environment. Following a degree in finance, I worked in a number of financial institutions honing my abilities in market analysis, financial planning, and investment strategies.

My love is teaching others about investing and personal finance. My goal in writing many books and articles has been to demystify financial ideas and give readers the information they need to make wise financial decisions. I write with a direct, useful style that emphasizes doable suggestions for daily living.

Along with writing, I lead webinars and seminars where I impart knowledge on how to successfully negotiate the financial world. I also write for financial journals and show up as a guest expert on financial news programs a lot. Whether they are new to investing or want to improve their approach, my mission is to enable people to take charge of their financial futures.

Beyond work, I like to hike, play the guitar, and spend time with my family. I think that balance is crucial and want to encourage people to strike a balance between their financial aspirations and their hobbies. I want to help people succeed and achieve financial security through my work, so having a good influence.

Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.